



Commercial PA Criteria
Effective: November 9, 2023

Prior Authorization: Xdemvy (lotilaner)

Products Affected: Xdemvy (lotilaner) ophthalmic solution

Medication Description: Xdemvy is a gamma-aminobutyric acid (GABA)-gated chloride channel inhibitor selective for mites. Inhibition of these GABA chloride channels causes a paralytic action in the target organism leading to its death. Xdemvy is not an inhibitor of mammalian GABA mediated chloride channels. Xdemvy, an ectoparasiticide (anti-parasitic) ophthalmic solution, is indicated for the treatment of Demodex blepharitis.

Covered Uses: indicated for the treatment of Demodex blepharitis

Exclusion Criteria:

1. None

Required Medical Information:

1. Diagnosis

Prescriber Restriction: Medication must be prescribed by, or in consultation with an optometrist or ophthalmologist

Age Restriction: 18 years and older

Coverage Duration: 12 months

Other Criteria:

Initial Approval Criteria

1. **Demodex Blepharitis**

- A. Patient has documented diagnosis of demodex blepharitis evidenced by (i **AND** ii)
 - i. Presence of at least mild erythema of the upper eyelid margin
 - ii. Presence of mites upon examination of eyelashes by light microscopy or presence of collarettes on slit lamp examination

References:

1. Xdemvy™ ophthalmic solution [prescribing information]. Irvine, CA: Tarsus; July 2023

November 2023



Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/09/2023

November 2023